SS  Vol.6 No.2 , February 2015
Heat Shock Protein 70 Expression in Giant Cell Tumor of Bone and Its Clinical Application
Abstract: Objective: To provide a better prognosis after the treatment of giant cell tumor of bone which is a common benign aggressive bone tumor by the use of thermoablation, Hsp70 expression of the tumor was explored and the relationship between the relative amount of expression of this protein and tumor recurrence was studied. Methods: Avascular parts of tumor tissues were collected from 11 patients, 3 male and 8 female with an average age of 32.27 years and were sent for the analysis of protein contents by the use of Western blot. A comparative protein analysis was used for the detection of Hsp70 and beta-actin. Monoclonal antibody was used for the identification of Hsp70. The measurement was carried out two times in one patient. The relationship between ratios of Hsp70/beta-actin and tumor recurrence during 3-year follow-up was carried out. Results: Tumor recurrence was found in 4 patients, 36.6% and none had lung metastasis. Significant HSP expression was found in all specimens. No patient with the ratio of HSP70/beta-actin expression lower than 0.66 had tumor recurrence. Sensitivity of the test was 75% and specificity was 100%. Conclusion: Expression of Hsp70 was found in giant cell tumor of bone and high relative expression of this protein related to tumor recurrence.
Cite this paper: Asavamongkokul, A. , Chotiyarnwonga, P. , Chotiyarnwonga, P. , Tirawanchai, N. and Waikakul, S. (2015) Heat Shock Protein 70 Expression in Giant Cell Tumor of Bone and Its Clinical Application. Surgical Science, 6, 26-34. doi: 10.4236/ss.2015.62005.

[1]   Tamura, Y., Torigoe, T., Kukita, K., Saito, K., Okuya, K., Kutomi, G., Hirata, K. and Sato, N. (2012) Heat-Shock Proteins as Endogenous Ligands Building a Bridge between Innate and Adaptive Immunity. Immunotherapy, 4, 841-852.

[2]   Taldone, T., Patel, H.J., Bolaender, A., Patel, M.R. and Chiosis, G. (2014) Protein Chaperones: A Composition of Matter Review (2008-2013). Expert Opinion on Therapeutic Patents, 24, 501-518.

[3]   Moon, A., Bacchini, P., Bertoni, F., Olvi, L.G., Santini-Araujo, E., Kim, Y.W. and Park, Y.K. (2010) Expression of Heat Shock Proteins in Osteosarcomas. Pathology, 42, 421-425.

[4]   Sedlackova, L., Spacek, M., Holler, E., Imryskova, Z. and Hromadnikova, I. (2011) Heat-Shock Protein Expression in Leukemia. Tumor Biology, 32, 33-44.

[5]   Guzhova, I.V., Shevtsov, M.A., Abkin, S.V., Pankratova, K.M. and Margulis, B.A. (2013) Intracellular and Extracellular Hsp70 Chaperone as a Target for Cancer Therapy. International Journal of Hyperthermia, 29, 399-408.

[6]   Juhasz, K., Lipp, A.M., Nimmervoll, B., Sonnleitner, A., Hesse, J., Haselgruebler, T. and Balogi, Z. (2013) The Complex Function of hsp70 in Metastatic Cancer. Cancers, 6, 42-66.

[7]   Dodd, K., Nance, S., Quezada, M., Janke, L., Morrison, J.B., Williams, R.T. and Beere, H.M. (2014) Tumor-Derived Inducible Heat-Shock Protein 70 (HSP70) Is an Essential Component of Anti-Tumor Immunity. Oncogene.

[8]   Sun, C., Li, H.L., Shi, M.L., Liu, Q.H., Bai, J. and Zheng, J.N. (2014) Diverse Roles of C-Terminal Hsp70-Interacting Protein (CHIP) in Tumorigenesis. Journal of Cancer Research and Clinical Oncology, 140, 189-197.

[9]   Uozaki, H., Ishida, T., Kakiuchi, C., Horiuchi, H., Gotoh, T., Iijima, T., Imamura, T. and Machinami, R. (2000) Expression of Heat Shock Proteins in Osteosarcoma and Its Relationship to Prognosis. Pathology—Research and Practice, 196, 665-673.

[10]   Murphy, M.E. (2013) The HSP70 Family and Cancer. Carcinogenesis, 34, 1181-1188.

[11]   Larsson, S.E., Lorentzon, R. and Boquist, L. (1975) Giant-Cell Tumor of Bone. A Demographic, Clinical, and Histopathological Study of All Cases Recorded in the Swedish Cancer Registry for the Years 1958 through 1968. Journal of Bone and Joint Surgery. American Volume, 57, 167-173.

[12]   Arthornthurasook, A. (1979) Giant Cell Tumor of Bones: 5 Years of Study. Journal of the Medical Association of Thailand, 62, 260-263.

[13]   Sung, H.W., Kuo, D.P., Shu, W.P., Chai, Y.B., Liu, C.C. and Li, S.M. (1982) Giant-Cell Tumor of Bone: Analysis of Two Hundred and Eight Cases in Chinese Patients. Journal of Bone and Joint Surgery. American Volume, 64, 755-761.

[14]   Pongkripetch, M. and Sirikulchayanonta, V. (1989) Analysis of Bone Tumors in Ramathibodi Hospital, Thailand during 1977-1986: Study of 652 Cases. Journal of the Medical Association of Thailand, 72, 621-628.

[15]   Settakorn, J., Lekawanvijit, S., Arpornchayanon, O., Rangdaeng, S., Vanitanakom, P., Kongkarnka, S., Cheepsattayakorn, R., Ya-In, C. and Thorner, P.S. (2006) Spectrum of Bone Tumors in Chiang Mai University Hospital, Thailand According to WHO Classification 2002: A Study of 1,001 Cases. Journal of the Medical Association of Thailand, 89, 780-787.

[16]   Chanchairujira, K., Jiranantanakorn, T., Phimolsarnti, R., Asavamongkolkul, A. and Waikakul, S. (2011) Factors of Local Recurrence of Giant Cell Tumor of Long Bone after Treatment: Plain Radiographs, Pathology and Surgical Procedures. Journal of the Medical Association of Thailand, 94, 1230-1237.

[17]   Turcotte, R.E., Wunder, J.S., Isler, M.H., Bell, R.S., Schachar, N., Masri, B.A., Moreau, G. and Davis, A.M., Canadian Sarcoma Group (2002) Giant Cell Tumor of Long Bone: A Canadian Sarcoma Group Study. Clinical Orthopaedics and Related Research, 397, 248-258.

[18]   Klenke, F.M., Wenger, D.E., Inwards, C.Y., Rose, P.S. and Sim, F.H. (2011) Recurrent Giant Cell Tumor of Long Bones: Analysis of Surgical Management. Clinical Orthopaedics and Related Research, 469, 1181-1187.

[19]   Niu, X.H., Zhang, Q., Hao, L., Ding, Y., Li, Y., Xu, H.R. and Liu, W.F. (2012) Giant Cell Tumor of the Extremity: Retrospective Analysis of 621 Chinese Patients from One Institution. The Journal of Bone and Joint Surgery (American), 94, 461-467.

[20]   van der Heijden, L., Dijkstra, P.D., van de Sande, M.A., Kroep, J.R., Nout, R.A., van Rijswijk, C.S., Bovée, J.V., Hogendoorn, P.C. and Gelderblom, H. (2014) The Clinical Approach toward Giant Cell Tumor of Bone. The Oncologist, 19, 550-561.

[21]   Takeuchi, A., Tsuchiya, H., Niu, X., Ueda, T., Jeon, D.G., Wang, E.H.M., Asavamongkolkul, A., Kusuzaki, K., Sakayama, K. and Kang, Y.K. (2011) The Prognostic Factors of Recurrent GCT: A Cooperative Study by the Eastern Asian Musculoskeletal Oncology Group. Journal of Orthopaedic Science, 16, 196-202.

[22]   Conti, A., Rodriguez, G.C., Chiechi, A., Blazquez, R.M., Barbado, V., Krènacs, T., Novello, C., Pazzaglia, L., Quattrini, I., Zanella, L., Picci, P., De Alava, E. and Benassi, M.S. (2011) Identification of Potential Biomarkers for Giant Cell Tumor of Bone Using Comparative Proteomics Analysis. American Journal of Pathology, 178, 88-97.

[23]   Larocca, L.M., Ranelletti, F.O., Maggiano, N., Rutella, S., La Barbera, E.O., Rumi, C., Serra, F., Voso, M.T., Piantelli, M., Teofili, L. and Leone, G. (1997) Differential Sensitivity of Leukemic and Normal Hematopoietic Progenitors to the Killing Effect of Hyperthermia and Quercetin Used in Combination: Role of Heat-Shock Protein-70. International Journal of Cancer, 73, 75-83.<75::AID-IJC13>3.0.CO;2-4

[24]   Ueda, G., Tamura, Y., Hirai, I., Kamiguchi, K., Ichimiya, S., Torigoe, T., Hiratsuka, H., Sunakawa, H. and Sato, N. (2004) Tumor-Derived Heat Shock Protein 70-Pulsed Dendritic Cells Elicit Tumor-Specific Cytotoxic T Lymphocytes (CTLs) and Tumor Immunity. Cancer Science, 95, 248-253.

[25]   Baena-Ocampo Ldel, C., Ramirez-Perez, E., Linares-Gonzalez, L.M. and Delgado-Chavez, R. (2009) Epidemiology of Bone Tumors in Mexico City: Retrospective Clinicopathologic Study of 566 Patients at a Referral Institution. Annals of Diagnostic Pathology, 13, 16-21.

[26]   Tan, S.S., Ahmad, I., Bennett, H.L., Singh, L., Nixon, C., Seywright, M., Barnetson, R.J., Edwards, J. and Leung, H.Y. (2011) GRP78 Up-Regulation Is Associated with Androgen Receptor Status, Hsp70-Hsp90 Client Proteins and Castrate-Resistant Prostate Cancer. Journal of Pathology, 223, 81-87.